{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:56:20Z","timestamp":1771977380526,"version":"3.50.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,19]]},"DOI":"10.7759\/cureus.22392","type":"journal-article","created":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T22:44:16Z","timestamp":1645310656000},"source":"Crossref","is-referenced-by-count":2,"title":["Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome"],"prefix":"10.7759","author":[{"given":"Samer","family":"Alkassis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdalaziz  M","family":"Awadelkarim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eltaib","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Halboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashid","family":"Alhusain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saivaishnavi","family":"Kamatham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isra","family":"Idris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg J","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al.. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017, 376:125-135. 10.1056\/NEJMoa1607427","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1795158","article-title":"Lutetium 177 dotatate induced acute myeloid leukemia","volume":"61","author":"Vallathol DH","year":"2020","unstructured":"Vallathol DH, Ali AZ, Alapati N, Manasa N, Vasanth P, Digumarti R. Lutetium 177 dotatate induced acute myeloid leukemia. Leuk Lymphoma. 2020, 61:3263-3265. 10.1080\/10428194.2020.1795158","journal-title":"Leuk Lymphoma"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.189712","article-title":"Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors","volume":"59","author":"Bergsma H","year":"2018","unstructured":"Bergsma H, van Lom K, Raaijmakers MH, et al.. Persistent hematologic dysfunction after peptide receptor radionuclide therapy with 177Lu-DOTATATE: incidence, course, and predicting factors in patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2018, 59:452-458. 10.2967\/jnumed.117.189712","journal-title":"J Nucl Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2893-5","article-title":"Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors","volume":"42","author":"Bodei L","year":"2015","unstructured":"Bodei L, Kidd M, Paganelli G, et al.. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015, 42:5-19. 10.1007\/s00259-014-2893-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.112.119347","article-title":"Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate","volume":"54","author":"Sabet A","year":"2013","unstructured":"Sabet A, Ezziddin K, Pape UF, et al.. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2013, 54:1857-1861. 10.2967\/jnumed.112.119347","journal-title":"J Nucl Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ph12030114","article-title":"Lutathera\u00ae: the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich U","year":"2019","unstructured":"Hennrich U, Kopka K. Lutathera\u00ae: the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals (Basel). 2019, 12:114. 10.3390\/ph12030114","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0078","article-title":"Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review","volume":"6","author":"Sonbol MB","year":"2020","unstructured":"Sonbol MB, Halfdanarson TR, Hilal T. Assessment of therapy-related myeloid neoplasms in patients with neuroendocrine tumors after peptide receptor radionuclide therapy: a systematic review. JAMA Oncol. 2020, 6:1086-1092. 10.1001\/jamaoncol.2020.0078","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0543","article-title":"High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy","volume":"23","author":"Brieau B","year":"2016","unstructured":"Brieau B, Hentic O, Lebtahi R, et al.. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy. Endocr Relat Cancer. 2016, 23:L17-L23. 10.1530\/ERC-15-0543","journal-title":"Endocr Relat Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/84301-lutetium-177-dotatate-induced-hemolytic-anemia-and-myelodysplastic-syndrome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:45:55Z","timestamp":1707507955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/84301-lutetium-177-dotatate-induced-hemolytic-anemia-and-myelodysplastic-syndrome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,19]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.22392","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2,19]]}}}